In line with this, studies analyzing the response rates of patients with cancer to ICB, such as anti-CTLA-4 in melanoma [123] or anti-PD-1 in non-small cell lung cancer (NSCLC) [124], observed a positive correlation between the mutational burden and the efficacy of the therapy. Here, PDCD1 is linked to non-small cell lung carcinoma.